Investor AB has undertaken to accept the public offer made September 2, by Agnafit Bidco for the shares in Swedish Orphan Biovitrum at a price per share of SEK 235.

Investor owns 107.6 million shares in Sobi, representing 35.4 percent of the capital and votes. The offer values Investor’s shares in Sobi at SEK 25.3 billion, corresponding to 21x the invested amount, or an IRR of 28 percent.

The bid, valuing the rare disease drugmaker at about 69.4 billion Swedish crowns ($8 billion), has been made by Advent International Corporation and Aurora Investment Pte Ltd, an affiliate of GIC Pte Ltd, through Agnafit Bidco AB. This the one of the largest buyout of a Nordic company in more than five years.

“We believe that the offer is financially attractive”

In 2010, Investor was instrumental in the creation of Sobi as the lead shareholder of its predecessors Swedish Orphan International (SOI) and Biovitrum.

“During Investor’s ownership, Sobi has successfully built a leading hemophilia franchise greatly benefitting patients. In addition, the company has with our support broadened its product portfolio within Hematology and Immunology, organically and through major acquisitions. This has created significant value for Sobi’s and Investor’s shareholders. Sobi’s Board of Directors has recommended Sobi’s shareholders to accept the offer. We believe that the offer is financially attractive. Advent International, the lead investor in Agnafit Bidco, has a well-proven track record of healthcare investments. Assuming completion of the offer, Investor’s financial position will be further strengthened. We intend to utilize this strength by continuing to invest in existing and new platform companies within Patricia Industries, selectively invest within Listed Companies as well as in EQT funds,” says Investor’s President and CEO Johan Forssell.

Lapse under certain circumstances

Investor’s undertaking to accept the offer will lapse under certain circumstances, including if a third party makes a competing offer for Sobi at a price per share of SEK 251 or more and such offer is unanimously recommended by the Sobi board. Full details are provided in Agnafit Bidco’s offer announcement press release today.

“Assuming that the offer is declared unconditional, the transaction is expected to be completed in the fourth quarter 2021.”

Assuming that the offer is declared unconditional, the transaction is expected to be completed in the fourth quarter 2021. Completion of the offer is conditional upon, among other things, the receipt by Agnafit Bidco of all necessary regulatory approvals and that the offer is accepted to such an extent that Agnafit Bidco becomes the owner of more than 90 percent of the shares in Sobi.

Agnafit Bidco AB

Agnafit Bidco AB is indirectly owned by Advent International Corporation and Aurora Investments Pte Ltd, a nominated investment vehicle of GIC Special Investments Pte Ltd, which is a subsidiary of GIC Pte Ltd.

Photo of Guido Oelkers, CEO, Sobi